<DOC>
	<DOCNO>NCT00644306</DOCNO>
	<brief_summary>In multiple myeloma , combination chemotherapy melphalan plus prednisone usedsince 1960s regard standard care elderly patient . We assess whether addition thalidomide 100 mg/day combination would improve survival .</brief_summary>
	<brief_title>Comparison Melphalan-Prednisone ( MP ) MP Plus Thalidomide Treatment Newly Diagnosed Very Elderly Patients ( &gt; 75 Years ) With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Stage II III multiple myeloma accord Durie Salmon criterion , patient older 75 year , previously untreated patient . Prior history another neoplasm ( except basocellular cutaneous cervical epithelioma ) Primary associate amylo√Ødosis World Health organisation performance index least 3 Significant renal insufficiency creatinine serum level 5.0 mg per deciliter Cardiac hepatic dysfunction Cerebral circulatory insufficiency Absolute contraindication corticosteroid Peripheral neuropathy clinically significant History venous thrombosis last 6 month HIV hepatitis B C positivity Patients geography , social , psychological condition might prevent adequate followup .</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Multiple Myeloma , elderly patient , thalidomide</keyword>
</DOC>